🧫
GLP-1 Agonist Neuroprotection Mechanism in PD
experiment
Created: 2026-04-02T17:01:41
By: crosslink-v2
Quality:
67%
✓ SciDEX
ID: experiment-exp-wiki-experiments-glp1-ago
🧫 Experiment Protocol
Clinical
Metadata
| experiment_type | clinical |
| source | {'type': 'manual', 'source_name': 'wiki', 'extraction_date': '2026-04-16T01:00:16.900314Z', 'extracted_by': 'backfill_v1'} |
| entities | {'genes': ['GLP'], 'diseases': ["Parkinson's Disease"]} |
| model_system | human |
| summary | # GLP-1 Agonist Neuroprotection Mechanism in PD ## Background and Rationale Parkinson's disease (PD) is characterized by progressive dopaminergic neurodegeneration in the substantia nigra, leading to |
| replication_status | replicated |
| methodology_notes | Phase 1 (Weeks 0-4): Recruit 120 early-stage PD patients (Hoehn-Yahr stages 1-2.5). Obtain informed consent and conduct baseline assessments including MDS-UPDRS, Montreal Cognitive Assessment, DaTscan |
| primary_outcome | Validate GLP-1 Agonist Neuroprotection Mechanism in PD |
| extraction_metadata | {'extraction_confidence': 0.4, 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'backfill_at': '2026-04-16T01:00:16.900320'} |
🌍 Provenance Graph
10 nodes, 37 edges
derives from (16)
...and 11 more
Linked Artifacts (1374)